Results 41 to 50 of about 26,895 (263)

Renoprotective Effects of SGLT2 Inhibitors

Heart Failure Clinics, 2022
SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption.
openaire   +4 more sources

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Cardiovascular Diabetology, 2020
Background Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong   +3 more
doaj   +1 more source

CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS [PDF]

Archiv Euromedica
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels.
Karol Wielgus, Maria Pawłowska, Piotr Bator, Adrian Bobrzyk, Angelika Wawryszuk, Weronika Kamińska, Karol Magiera, Jan Ramian, Grzegorz Łyko, Maria Antos   +9 more
openaire   +1 more source

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner

Advanced Science, EarlyView.
Canagliflozin treatment reshapes the gut microbiota in DKD and elevates levels of melibiose, a metabolite derived from Roseburia intestinalis. Melibiose directly binds to and enhances the enzymatic activity of glyoxalase 1, leading to decreased methylglyoxal accumulation.
Wei Zhang, Yi Song, Changkun Li, Yuanyuan Luo, Mingwei Shao, Feng Guo, Fangyi Wei, Xunjie Fan, Wenwen Guo, Fengmei Xu, Yanhong Sang, Dongming Zhang, Yanhong Zhou, Lianwei Wang, Zhiqiang Kang, Yingjun Yang, Chunhua Song, Yanxia Liu, Xiaojun Ma, Jiao Wang, Chong Li, Shengnan Ma, Lin Zhao, Zhi Qin, Guolan Xing, Qiubo Zhao, Jun Li, Shumin Song, Dan Zhao, Ting Huang, Qingzhu Wang, Yanyan Zhao, Guijun Qin   +32 more
wiley   +1 more source

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes

Journal of Diabetes Investigation, 2021
Aims/Introduction This study aimed to investigate the risk of diabetic ketoacidosis (DKA) in insulin‐treated type 1 diabetes patients administered sodium–glucose cotransporter 2 (SGLT2) inhibitors in real‐world clinical practice. Materials and Methods We
Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda, Akira Shimada   +3 more
doaj   +1 more source

Chances and risks of SGLT2 inhibitors [PDF]

Naunyn-Schmiedeberg's Archives of Pharmacology, 2011
Type II diabetes mellitus (T2DM) is characterised by relative insulin deficiency caused by resistance of important target organs like liver and skeletal muscle towards insulin. During the course of the disease, pancreatic insulin production becomes decreased, and absolute insulin deficiency results (Kahn 2003).
openaire   +2 more sources

G6PC Downregulation Promotes Renal Calcium Oxalate Stone Formation via Lactate‐Induced SNAIL1 K206 Lactylation and Epithelial‐Mesenchymal Transition

Advanced Science, EarlyView.
In renal calcium oxalate stone formation, G6PC downregulation leads to lactate accumulation. This lactate mediates CBP/p300‐dependent lactylation of SNAIL1 at K206, promoting its nuclear translocation. Nuclear SNAIL1 activates the TGF‐β/SMAD3 pathway, driving epithelial‐mesenchymal transition and fibrosis, which ultimately facilitates crystal ...
Kai Liu, Boming Zhang, Ruixin Fan, Chen Duan, Yangjun Zhang, Huahui Wu, Xiangyang Yao, Xiongmin Mao, Bo Li, Youmiao Zeng, Zhenzhen Xu, Yang Wang, Mengcheng Luo, Xinyu Xu, Ninghan Feng, Heng Li, Hua Xu   +16 more
wiley   +1 more source

Blood Pressure‐Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real‐World Data Analysis

The Journal of Clinical Hypertension
Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated blood pressure (BP)‐lowering effects; however, most studies included patients taking antihypertensive medications.
Reina Ito, Michihiro Satoh, Hideaki Hashimoto, Hiroki Nobayashi, Seiya Izumi, Maya Toyama, Yutaro Iwabe, Yuya Suzuki, Takuo Hirose, Shingo Nakayama, Takahisa Murakami, Masato Sasaki, Hirohito Metoki   +12 more
doaj   +1 more source

SGLT2 inhibitors in cardiovascular medicine [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
Varzideh, Fahimeh, Kansakar, Urna, Santulli, Gaetano   +2 more
openaire   +3 more sources

Targeting ANGPTL3 and IL‐33/ST2 Ameliorates Diabetic Kidney Disease by Reducing Lipotoxicity, Alleviating Inflammation and Inhibiting Fibrosis

Advanced Science, EarlyView.
Dual targeting of ANGPTL3 and IL‐33/ST2 attenuates diabetic kidney disease by reprogramming lipid–inflammatory crosstalk. This strategy reduces renal lipotoxicity, suppresses inflammatory activation, and limits fibrotic remodeling, thereby preserving kidney structure and function and highlighting a mechanism‐guided therapeutic approach for metabolic ...
Zhuojin Li, Zhonglian Cao, Rongrui Zhou, Xu Cheng, Xiaozhi Hu, Shuwen Xu, Zihan Dou, Ling Du, Dianwen Ju   +8 more
wiley   +1 more source